DJIA 17,039.49 60.36 0.36%
NASDAQ 4,532.10 5.62 0.12%
S&P 500 1,992.37 5.86 0.29%
market minute promo


company name or ticker
Company Photos
(Click to zoom)

3 Stocks Reiterated As A Buy: EBAY, BMY, EMC

Galectin Therapeutics Reports First Patient Dosed in Cohort 1 of Phase 1B Clincial Trial of GR-MD-02

Galectin Therapeutics Reports First Patient Dosed in Cohort 1 of Phase 1B Clincial Trial of GR-MD-02 in Combo with Ipilimumab in Metastatic Melanoma

Notable ETF Inflow Detected - IWB, AMGN, UNH, BMY

Bristol-Myers/Pfizer Commence Phase IV Study on Eliquis - Analyst Blog

What You Need to Know About Johnson & Johnson's Best-Selling Drugs

Johnson & Johnson's new drugs are driving sales growth; but new competition from AbbVie and Bristol-Myers Squibb create risk.

3 Stocks Reiterated As A Buy: MDLZ, BMY, MO

UnitedHealth Group Up on Weak Day for the Dow

Should Roche Buy Exelixis?

A successful phase 3 study has started rumors that Roche may bid for Exelixis

Keep Calm and Carry On, J&J

Thanks to J&J's new drugs, the company's Q2 earnings were solid. But a jittery market focused on the bad news.

Cramer's Lightning Round - General Electric Needs To Bring Good Things To Life (7/15/14)

See More Articles...